Tinea Corporis Companies

ID: MRFR/Pharma/5373-HCR

90 Pages

Rahul Gotadki

Last Updated: February 16, 2025

Tinea corporis, commonly known as ringworm, is a fungal infection that affects the skin. Several companies specialize in developing and manufacturing products to treat and manage this condition. These companies play a crucial role in providing effective solutions to individuals suffering from tinea corporis, offering a range of antifungal medications, topical creams, and other therapeutic options.

Tinea Corporis Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.14%

2024 Market Size$ 14.21 Billion

2025 Market Size$ 14.96 Billion

2035 Market Size$ 22.3 Billion

Key Players

Bayer AG

Novartis AG

GlaxoSmithKline plc

Johnson & Johnson

Sanofi S.A.

Pfizer Inc.

Trends

Rising Awareness of Skin Health
Advancements in Treatment Options
Growth of E-commerce in Healthcare

Opportunities

Market Growth Projections
Rising Healthcare Expenditure
Growing Awareness and Education

Summary Table of Contents Segmentation Download PDF

Customize Report

Certified Researchers

Top Industry Leaders in the Tinea Corporis Market

Latest Tinea Corporis Companies Updates:

Lonza Expands API Manufacturing Capacity with Acquisition of Capsugel Dosage Form Solutions: This December 2023 acquisition strengthens Lonza's HPAPI capabilities and expands their geographic reach.

Bolloré acquires Chemours' Advanced Process Technologies (APT) business: This November 2023 deal grants Bolloré access to APT's expertise in HPAPI development and manufacturing, particularly for small molecules.

Pfizer Collaborates with WuXi AppTec for HPAPI Development and Manufacturing: This ongoing partnership leverages WuXi's extensive HPAPI capabilities to support Pfizer's pipeline of potent drugs.

Bristol Myers Squibb Receives FDA Approval for Celdura (Paclitaxel) Injectable Emulsion: This November 2023 approval expands treatment options for cancer patients with a new formulation of a potent HPAPI.

Eli Lilly Announces Positive Phase III Results for Lorlatinib for ALK-positive Non-Small Cell Lung Cancer: This promising development in December 2023 could lead to a new targeted therapy using an HPAPI.

List of Tinea Corporis Key companies in the market:

Taro Pharmaceuticals., Inc.
Teva Pharmaceuticals, Inc.
Glenmark Pharmaceuticals Inc
Breckenridge Pharmaceutical, Inc.
NorthStar Rx LLC
Aurobindo Pharma Limited,
Camber Pharmaceuticals, Inc.
AvKare, Inc.
Novartis AG
Sebela Pharmaceuticals, Inc.,
Bayer AG

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”